WaveMan
WaveMan · Company
SLXN · Silexion Therapeutics Corp
> Search tickers & screens ⌘K
LIVE
← All companies

SLXN Silexion Therapeutics (SLXN) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0002022416
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
6
13F, latest reported quarter

Silexion Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Silexion Therapeutics Corp in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Shirvan Mitchell
CSO and CDO
SELL
2026-03-30 SECtraded 2026-03-26
22,818
$31.0K
-98.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 81.8% of the 27,889 shares held after it.
  • No other insider sold within 30 days.
  • 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CSO and CDO Shirvan Mitchell sold about $31.0K of SLXN on Mar 26, 2026, the largest insider sale at the company on our record; 6 funds added in the latest 13F quarter.
1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
6 funds bought in last quarter
below 92% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.9% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 60% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch SLXN

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-99.5%12M
-100%-65%-31%+3%2025-102025-122026-022026-042026-062026-082026-10 2026-03-26 · Shirvan Mitchell sold $31.0K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SLXN: institutional holders (13F)

13F holdings, latest reported quarter
Oasis Management Co Ltd.
11,111 sh
$28.3K
Polar Asset Management Partners Inc.
743,475 sh
$20.8K
Linden Advisors LP
337,500 sh
$9.5K
ARISTEIA CAPITAL, L.L.C.
236,546 sh
$6.6K
Clear Street Group Inc.
218,165 sh
$6.6K

Congress trades in SLXN

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SLXN planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 6 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

SLXN financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$12.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-17,022%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-278.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-721.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
0.00x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no debt line filed
FCF yield
-1,278%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing EPS growth -97%, PEG needs growth
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Operating income-$11.6M-$12.6M-$4.7M
Net income-$11.9M-$16.5M-$5.1M
EPS (diluted)89.613,955.11659.55
Operating cash flow-$10.8M-$8.4M-$4.5M
Cash$6.0M$1.2M$4.6M
SEC XBRL, fiscal years, as known on 2026-10-28

SLXN Stock Sonar score 3/7 axes

Find similar shapesCompare

SLXN ranks highest on risk and compliance (67th percentile) and institutional and government (8th), and lowest on profitability (3rd), among Pharma & Biotech peers.

Profitability
3
Inputs
  • Return on equity-17022% · 1 pct, sector of 545
  • Return on assets-278.0% · 7 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-721.3% · 2 pct, sector of 576
Institutional and government
8
Inputs
  • Funds adding, latest quarter6 · 8 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
67
Inputs
  • Short interest, % of float+2.9% · 67 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Financial health, Growth, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies